Headlines about BioSpecifics Technologies Corp. (NASDAQ:BSTC) have been trending somewhat positive this week, according to Alpha One Sentiment. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioSpecifics Technologies Corp. earned a news sentiment score of 0.17 on Alpha One’s scale. Alpha One also gave headlines about the biopharmaceutical company an impact score of 81 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected AlphaOne’s analysis:
- BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Regulation FD Disclosure (4-traders.com)
- Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : April 20, 2017 (finance.yahoo.com)
- BIOSPECIFICS TECHNOLOGIES CORP : Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids (finance.yahoo.com)
- Very Positive News Coverage Somewhat Likely to Impact BioSpecifics Technologies Corp. (BSTC) Stock Price (americanbankingnews.com)
Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded down 0.28% on Friday, hitting $54.35. The company’s stock had a trading volume of 6,595 shares. The company has a market cap of $389.25 million, a price-to-earnings ratio of 34.84 and a beta of 1.31. BioSpecifics Technologies Corp. has a 52 week low of $32.39 and a 52 week high of $58.21. The stock’s 50 day moving average is $53.48 and its 200-day moving average is $50.74.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) last posted its earnings results on Wednesday, March 15th. The biopharmaceutical company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. The company earned $6.62 million during the quarter, compared to analysts’ expectations of $6.76 million. BioSpecifics Technologies Corp. had a net margin of 43.13% and a return on equity of 22.74%. On average, equities research analysts anticipate that BioSpecifics Technologies Corp. will post $1.74 earnings per share for the current year.
Separately, Zacks Investment Research lowered BioSpecifics Technologies Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, January 10th.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Very Likely to Affect BioSpecifics Technologies Corp. (BSTC) Stock Price” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/04/21/somewhat-positive-media-coverage-very-likely-to-effect-biospecifics-technologies-corp-bstc-stock-price-updated.html.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.